Goldman Sachs analyst Salveen Richter raised the firm’s price target on Arcus Biosciences (RCUS) to $16 from $14 and keeps a Neutral rating on the shares. Arcus reported Q3 EPS and provided updates and timelines for its programs, including casdatifan in clear-cell renal cell carcinoma, where the Phase 3 study in the post-IO setting continues to enroll, but enrollment has been paused for the Phase 1b/3 1L trial to assess the combination regimen’s safety profile, the analyst tells investors in a research note. Goldman continues to view cas’s profile as differentiated vs. Merck’s (MRK) competitor drug Welireg.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Arcus Biosciences price target raised to $35 from $33 at Wedbush
- Arcus Biosciences price target raised to $56 from $54 at Citi
- Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
- Arcus Biosciences Reports Promising Q3 2025 Results
- Arcus Biosciences reports Q3 EPS ($1.27), consensus ($1.29)